GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » ROE % Adjusted to Book Value

Avacta Group (LSE:AVCT) ROE % Adjusted to Book Value : -7.86% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group ROE % Adjusted to Book Value?

Avacta Group's ROE % for the quarter that ended in Dec. 2023 was -120.47%. Avacta Group's PB Ratio for the quarter that ended in Dec. 2023 was 15.33. Avacta Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -7.86%.


Avacta Group ROE % Adjusted to Book Value Historical Data

The historical data trend for Avacta Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group ROE % Adjusted to Book Value Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.03 -9.75 -6.54 -8.09 -7.60

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.73 -5.35 -13.84 -7.95 -7.86

Competitive Comparison of Avacta Group's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Avacta Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Avacta Group's ROE % Adjusted to Book Value falls into.



Avacta Group ROE % Adjusted to Book Value Calculation

Avacta Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-116.57% / 15.33
=-7.60%

Avacta Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-120.47% / 15.33
=-7.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Avacta Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (LSE:AVCT) Business Description

Industry
Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines